OREX - Orexigen Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue33,70924,45955,521
Cost of Revenue7,995--
Gross Profit25,71424,45955,521
Operating Expenses
Research Development38,02340,75057,412
Selling General and Administrative41,35443,76228,639
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-56,970-60,053-30,530
Income from Continuing Operations
Total Other Income/Expenses Net40,42918888
Earnings Before Interest and Taxes-16,541-59,865-30,442
Interest Expense7,8507,4467,083
Income Before Tax-24,391-67,311-37,525
Income Tax Expense1331,376-
Minority Interest---
Net Income From Continuing Ops-24,524-68,687-37,525
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-24,524-68,687-37,525
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-24,524-68,687-37,525